title: Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.
authors.affiliation: Université Versailles Saint-Quentin-en-Yvelines, Versailles, France philippe.saiag@uvsq.fr.
authors.forename: Marie-Florence
authors.initials: MF
authors.lastname: de Maleissye
authors.affiliation: Université Versailles Saint-Quentin-en-Yvelines, Versailles, France philippe.saiag@uvsq.fr.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Nicolas
authors.affiliation: Université Versailles Saint-Quentin-en-Yvelines, Versailles, France philippe.saiag@uvsq.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Saiag
mesh_terms: D000200:Action Potentials; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D011129:Polyradiculoneuropathy / Q000139:chemically induced*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000139:chemically induced
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab